SEATTLE, Oct. 28 /PRNewswire-FirstCall/ -- Dendreon Corporation will announce financial results for the third quarter 2005 on Friday, November 4, 2005 and will hold a webcast teleconference at 11:00 a.m. Eastern standard time that day. Company management will discuss financial results from the third quarter and provide a general corporate update. Access to the discussion may be obtained as follows:
Conference Call LIVE Access on November 4, 2005, 8:00 a.m. PST; 11:00 a.m. EST -- Phone 800-357-9448 (domestic) or +1-312-461-9314 (international) -- Webcast connection through the Dendreon website at www.dendreon.com in the Investors/Webcast section. REPLAY Access: -- Phone replay available at 2:00 p.m. EST for 3 days by calling 888-203-1112 (domestic) or +1-719-457-0820 (international); Passcode: 4751256 -- Webcast replay will be available for 90 days from the Dendreon website at www.dendreon.com in the Investors/Webcast section.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the development of innovative cancer treatments. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon’s product pipeline also includes monoclonal antibody and small molecule product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com.
Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Further information on the factors and risks that could affect Dendreon’s business, financial condition and results of operations are contained in Dendreon’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.
Dendreon Corporation
CONTACT: Monique M. Greer, Sr. Director, Corporate Communications ofDendreon Corporation, +1-206-829-1500
Web site: http://www.dendreon.com/
